

Hanny Al-Samkari

List of Publications by Citations

Source: <https://exaly.com/author-pdf/562452/hanny-al-samkari-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

1,913
citations

21
h-index

42
g-index

120
ext. papers

2,887
ext. citations

5.9
avg, IF

6.14
L-index

#	Paper	IF	Citations
110	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <i>Blood</i> , 2020 , 136, 489-500	2.2	642
109	Hemophagocytic Lymphohistiocytosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018 , 13, 27-49	34	159
108	Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. <i>Annals of Internal Medicine</i> , 2020 , 173, 989-1001	8	79
107	Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. <i>Haematologica</i> , 2018 , 103, 1433-1443	6.6	70
106	Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. <i>British Journal of Anaesthesia</i> , 2019 , 122, 19-31	5.4	47
105	Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2021 , 174, 622-632	8	41
104	ABO phenotype and death in critically ill patients with COVID-19. <i>British Journal of Haematology</i> , 2020 , 190, e204-e208	4.5	37
103	The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. <i>Haematologica</i> , 2018 , 103, e169-e172	6.6	37
102	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719841735	5.7	36
101	The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. <i>European Journal of Haematology</i> , 2020 , 104, 79-87	3.8	36
100	Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. <i>American Journal of Hematology</i> , 2018 , 93, 1501-1508	7.1	35
99	Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. <i>Journal of Internal Medicine</i> , 2019 , 285, 223-231	10.8	30
98	The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. <i>Cancers</i> , 2018 , 10,	6.6	28
97	Romiplostim for the management of perioperative thrombocytopenia. <i>British Journal of Haematology</i> , 2018 , 182, 106-113	4.5	27
96	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. <i>Haematologica</i> , 2021 , 106, 2161-2169	6.6	26
95	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020 , 4, 9-18	7.8	26
94	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 275-288	5.3	23

93	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <i>Blood Advances</i> , 2019 , 3, 3770-3779	7.8	23
92	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. <i>Haematologica</i> , 2021 , 106, 1148-1157	6.6	23
91	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1497-1506	8.9	22
90	Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. <i>Annals of Hematology</i> , 2019 , 98, 581-588	3	22
89	Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. <i>Journal of Blood Medicine</i> , 2019 , 10, 313-321	2.3	21
88	d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2021 , 49, e500-e511	1.4	19
87	The variable manifestations of disease in pyruvate kinase deficiency and their management. <i>Haematologica</i> , 2020 , 105, 2229-2239	6.6	17
86	Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018 , 183, 168	4.5	17
85	An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2673-2677	3.8	15
84	Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. <i>Orphanet Journal of Rare Diseases</i> , 2019 , 14, 256	4.2	15
83	Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. <i>Vascular Health and Risk Management</i> , 2019 , 15, 175-186	4.4	14
82	Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation Assays. <i>American Journal of Hematology</i> , 2018 , 93, 1082	7.1	13
81	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). <i>American Journal of Hematology</i> , 2020 , 95, 1479-1485	7.1	13
80	Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. <i>American Journal of Hematology</i> , 2020 , 95, 1180	7.1	12
79	Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the gene polymorphism. <i>Journal of Medical Genetics</i> , 2019 , 56, 39-42	5.8	12
78	Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. <i>Blood</i> , 2021 , 137, 888-895	2.2	12
77	Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	11
76	An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. <i>Haemophilia</i> , 2020 , 26, 1038-1045	3.3	10

75	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. <i>Blood Advances</i> , 2019 , 3, 3515-3521	7.8	10
74	SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients. <i>Blood</i> , 2021 ,	2.2	10
73	Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 807-812	5.1	9
72	Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies. <i>Otolaryngology - Head and Neck Surgery</i> , 2019 , 160, 368	5.5	8
71	The role of romiplostim for pediatric patients with immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2020 , 11, 2040620720912992	5.7	8
70	Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease. <i>Drugs of Today</i> , 2018 , 54, 647-655	2.5	8
69	Cancer and thrombosis: new insights to an old problem. <i>JMV-Journal De Medecine Vasculaire</i> , 2020 , 45, 6S8-6S16	0.6	8
68	Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. <i>Expert Review of Hematology</i> , 2021 , 14, 437-448	2.8	8
67	The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. <i>British Journal of Haematology</i> , 2021 , 192, 1092-1096	4.5	8
66	Severe autoimmune hemolytic anemia following receipt of SARS-CoV-2 mRNA vaccine. <i>Transfusion</i> , 2021 , 61, 3267-3271	2.9	8
65	Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. <i>Chest</i> , 2019 , 155, 1226-1233	5.3	7
64	Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 81-83	5.1	7
63	Striving for full disclosure-An intergenerational challenge. <i>Cancer</i> , 2020 , 126, 1150-1151	6.4	7
62	An evaluation of avatrombopag for the treatment of thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 273-280	4	7
61	The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. <i>Platelets</i> , 2021 , 1-7	3.6	7
60	Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. <i>Platelets</i> , 2021 , 1-8	3.6	7
59	Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability. <i>American Journal of Hematology</i> , 2018 , 93, E156-E158	7.1	6
58	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 71-79	3.1	6

57	Recurrence of Acute Intermittent Porphyria After Liver Transplantation. <i>Annals of Internal Medicine</i> , 2019 , 170, 904-905	8	6
56	Thrombophilia evaluation in pulmonary embolism. <i>Current Opinion in Cardiology</i> , 2019 , 34, 603-609	2.1	6
55	Comorbidities and complications in adults with pyruvate kinase deficiency. <i>European Journal of Haematology</i> , 2021 , 106, 484-492	3.8	6
54	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. <i>Haematologica</i> , 2018 , 103, e492-e495	6.6	6
53	Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice. <i>Journal of Blood Medicine</i> , 2021 , 12, 653-664	2.3	5
52	Emapalumab for the treatment of hemophagocytic lymphohistiocytosis. <i>Drugs of Today</i> , 2020 , 56, 439-446		4
51	Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 20406207211066070	5.7	4
50	Characterization of the severe phenotype of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2020 , 95, E281	7.1	4
49	Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. <i>Angiogenesis</i> , 2021 , 1	10.6	4
48	Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. <i>British Journal of Haematology</i> , 2019 , 187, e61-e64	4.5	3
47	Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1852-1863	15.4	3
46	Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COVS.2.S Vaccination: A Case Report. <i>Annals of Internal Medicine</i> , 2021 , 174, 1632-1633	8	3
45	Health-Related Quality of Life and Fatigue in Children and Adults with Pyruvate Kinase Deficiency. <i>Blood Advances</i> , 2021 ,	7.8	3
44	Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.. <i>Lancet Haematology</i> , 2022 , 9, e179-e189	14.6	3
43	A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 1340-1342	5.1	2
42	Anticoagulation and Enzalutamide: Caution Over Convenience. <i>Journal of Oncology Practice</i> , 2017 , 13, 728-729	3.1	2
41	Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia. <i>Blood</i> , 2016 , 128, 3748-3748	2.2	2
40	Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study. <i>Blood</i> , 2021 , 138, 1015-1015	2.2	2

39	Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1	5.1	2
38	Cancer-associated thrombosis: Where do we stand?. <i>Advances in Cell and Gene Therapy</i> , 2020 , 3, e73	1.2	2
37	Tissue Plasminogen Activator in Critically Ill Adults with COVID-19. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1917-1921	4.7	2
36	Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. <i>Haemophilia</i> , 2021 , 27, e270-e273	3.3	2
35	How to focus our efforts in improving prognostic disclosure in oncology. <i>Cancer</i> , 2020 , 126, 2716-2717	6.4	1
34	Partial Suture Fusion in Nonsyndromic Single-Suture Craniosynostosis. <i>Cleft Palate-Craniofacial Journal</i> , 2020 , 57, 499-505	1.9	1
33	Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature. <i>Blood</i> , 2020 , 136, 45-46	2.2	1
32	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. <i>Blood</i> , 2020 , 136, 30-32	2.2	1
31	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2348-2354	15.4	1
30	Giving hereditary haemorrhagic telangiectasia the attention it deserves. <i>Lancet Haematology</i> , 2021 , 8, e472-e474	14.6	1
29	Optimal anticoagulant treatment of cancer-associated venous thromboembolism remains unclear. <i>BMJ Evidence-Based Medicine</i> , 2019 , 24, 115-116	2.7	1
28	Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. <i>JAMA Network Open</i> , 2021 , 4, e2119812	10.4	1
27	Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome. <i>Blood Advances</i> , 2021 , 5, 3850-3854	7.8	1
26	Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.. <i>British Journal of Haematology</i> , 2022 ,	4.5	1
25	A Precision Medicine Approach to Hereditary Hemorrhagic Telangiectasia and Complex Vascular Anomalies.. <i>Journal of Thrombosis and Haemostasis</i> , 2022 ,	15.4	1
24	Mitapivat versus Placebo for Pyruvate Kinase Deficiency.. <i>New England Journal of Medicine</i> , 2022 , 386, 1432-1442	59.2	1
23	Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00118	4.2	0
22	Venous and Arterial Thrombosis Following Abemaciclib Therapy for Metastatic Breast Cancer. <i>Blood</i> , 2021 , 138, 4063-4063	2.2	0

21	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 586-586	0
20	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. <i>Blood</i> , 2021 , 138, 848-848	2.2 0
19	Severe babesiosis with associated splenic infarcts and asplenia. <i>Baylor University Medical Center Proceedings</i> , 2021 , 34, 597-599	0.6 0
18	An Eltrombopag Red (Plasma) Alert. <i>Acta Haematologica</i> , 2021 , 144, 227-228	2.7 0
17	Response to rituximab in children and adults with immune thrombocytopenia (ITP). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12587	5.1 0
16	Predictors of mortality and outcomes of liver transplant in spur cell hemolytic anemia. <i>American Journal of Hematology</i> , 2021 , 96, 1611-1620	7.1 0
15	Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2021 , 96, 1563-1568	7.1 0
14	Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.. <i>Pediatric Blood and Cancer</i> , 2021 , e29447	3 0
13	Characteristics of Children and Adults Treated with Rituximab for Immune Thrombocytopenia (ITP). <i>Blood</i> , 2020 , 136, 38-39	2.2
12	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020 , 136, 14-14	2.2
11	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. <i>Blood</i> , 2020 , 136, 4-5	2.2
10	Hospitalization As a Risk Factor for Bleeding: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study. <i>Blood</i> , 2021 , 138, 1915-1915	2.2
9	Predictors of Mortality and Outcomes of Liver Transplant in Spur Cell Hemolytic Anemia. <i>Blood</i> , 2021 , 138, 1995-1995	2.2
8	TPO versus TPO: the good, the bad, and the to be determined. <i>British Journal of Haematology</i> , 2021 , 195, 653-654	4.5
7	An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. <i>Blood</i> , 2019 , 134, 1060-1060	2.2
6	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. <i>Blood</i> , 2019 , 134, 2175-2175	2.2
5	New therapeutic horizons in Wiskott-Aldriech syndrome. <i>British Journal of Haematology</i> , 2021 , 192, 231-232	2.2
4	Recognition and management of vascular lesions in von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2122-2124	15.4

- 3 Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia.. *Drugs of Today*, **2022**, 58, 105-116 2.5
- 2 Platelet clump visible to the naked eye in type 2B von Willebrand disease.. *Blood*, **2021**, 138, 2742 2.2
- 1 Doxycycline for bleeding in hereditary hemorrhagic telangiectasia: When low-hanging fruit meets inconvenient data.. *Journal of Thrombosis and Haemostasis*, **2022**, 20, 1067-1069 15.4